Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
+$0.04 today
- Market cap
- $227.58M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
Volume 4.13M
Average 3.33M
CABA Operating Cash Flow
Cash generated by the company's core business operations during the period.
Cabaletta Bio, Inc.NASDAQ: CABA
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow grows, but more slowly than its trailing trend
Q1 FY2026 operating cash flow of $42.56M (cash outflow) rose 38.2% year over year, behind the +50.3% change in trailing-twelve-month operating cash flow. Sequentially, it rose 20.4% from the prior quarter. Over 3 fiscal years it compounded at +41.4% a year.
Context
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +38.2% toward the trailing-twelve-month pace of +50.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (131.08M) USD
- Year-over-year change
- -48.6%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (131.08M) | -48.6% |
| FY2024 | 2024-12-31 | (88.22M) | -64.8% |
| FY2023 | 2023-12-31 | (53.55M) | -15.5% |
| FY2022 | 2022-12-31 | (46.38M) | -36.0% |
| FY2021 | 2021-12-31 | (34.11M) | — |
Operating Cash Flow vs competitors
How CABA compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +50.3% is the 3rd highest of 11, against a peer median of +11.9%.
- Over three fiscal years its annual growth of +41.4% compares with a peer median of +3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $150.39M USD | +12.5% | +62.1% | — | |
| LTM Mar 2026 | $147.86M USD | +17.2% | +3.0% | — | |
| LTM Mar 2026 | $142.84M USD | +50.3% | +41.4% | — | |
| LTM Mar 2026 | $140.5M USD | -32.5% | -2.3% | 363.1% | |
| LTM Mar 2026 | $133.8M USD | -23.6% | -4.0% | 431600.0% | |
| LTM Mar 2026 | $109.23M USD | -44.6% | -12.2% | — | |
| LTM Mar 2026 | $101.54M USD | +2.2% | +13.9% | 5037.0% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $97.99M USD | +11.4% | +21.8% | — |
| LTM Mar 2026 | $92.63M USD | +105.1% | — | — | |
| FY2025 | A$62.05M AUD | +78.2% | +27.1% | 1230.2% | |
| LTM Mar 2026 | €48.04M EUR | +29.6% | -9.5% | 357.4% | |
| Peer median (excluding CABA) | — | +11.9% | +3.0% | 1230.2% | |
Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Depreciation & Amortization | 733K | 1.18M | 1.43M | 1.71M | 1.65M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.8M | 6.9M | 11.34M | 19.47M | 20.94M |
| Change in Working Capital | 5.58M | (4.3M) | 101K | 1.61M | (379K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 975K | (28K) | 1.68M | 1.01M | 1.55M |
| Other Working Capital | 4.61M | (4.27M) | (1.57M) | 600K | (1.93M) |
| Other Non-Cash Items | 62K | 2.82M | 1.26M | 4.86M | 14.57M |
| Operating Cash Flow | (34.11M) | (46.38M) | (53.55M) | (88.22M) | (131.08M) |
| Capital Expenditures | (1.17M) | (2.45M) | (687K) | (2.21M) | (1.23M) |
| Acquisitions (Net) | 0 | 24.76K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (49.76M) | (84.26M) | 0 | (99.04M) |
| Sales of Investments | 7.17M | 25M | 62.5M | 49.5M | 50M |
| Other Investing Activities | 0 | (24.76K) | 0 | 0 | 0 |
| Investing Cash Flow | 6M | (27.22M) | (22.45M) | 47.29M | (50.27M) |
| Debt Repayment | 0 | 0 | 0 | (897K) | (6.26M) |
| Common Stock Issued | 48.25M | 32.86M | 185.2M | 10.88M | 106.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 650K | 127K | 2.43M | 1.7M | 0 |
| Financing Cash Flow | 48.9M | 32.98M | 187.63M | 11.68M | 100.35M |
| Effect of Forex Changes | 0 | 0 | 0 | (20K) | 19K |
| Net Change in Cash | 20.79M | (40.62M) | 111.63M | (29.28M) | (80.98M) |
| Free Cash Flow | (35.28M) | (48.83M) | (54.24M) | (90.43M) | (132.31M) |
Cabaletta Bio, Inc.
NASDAQ:CABA
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.